HubSpot, Inc. (HUBS)

HubSpot is trading near the bottom of its 52-week range after a sharp year-long slide, and the latest quarterly report did little to lift the stock. The shares closed at $196.99, down 4.34% on the last session, and sit 12.53% below the 20-day EMA, 13.59% below the 200-day SMA and 14.20% below the 50-day SMA. The market is pricing in more than a beat: growth is slower than the sector and the valuation still carries a premium.

The stock has now beaten the EPS estimate in each of the last seven reports, and in six of those cases the price moved lower in the first session. Investors appear to be focused on the top line and the valuation rather than on earnings surprises.

At a trailing P/E of 47.58, the stock trades a premium to peers and 35.6% above the sector median P/E of 35.1. Its price-to-sales ratio of 2.68 is 64.7% below the sector median of 7.6, so on sales the shares look cheap, but the sales multiple reflects a company with a 5.95% net profit margin and a return on equity of 12.25%, which is below the sector median of 13.4%. The balance sheet is light, with a debt-to-equity ratio of 0.14, which supports the company's health rating of 3 out of 5.

Of 35 analysts with a current rating, eight rate the stock buy or strong buy, 25 rate it hold and two rate it sell or strong sell. The consensus is Hold. UBS downgraded the stock to Neutral from Buy on October 27, 2026, and Barclays downgraded it to Equal-Weight from Overweight on October 12, 2026. Buy ratings numbered 15 of 34 three months earlier, so the number of buy ratings has fallen. The median 12-month target of $257.11 still sits 30.5% above the price.

Insiders sold stock worth $70.5M over the last 18 months across 32 sales, against $2.8M of open-market purchases from four buys. Insider sales are often planned in advance or made to cover tax on vesting shares, so they are a weaker signal than open-market purchases, but the scale of selling against buying is a point investors will notice.

The base case for the coming months is that HubSpot stays under its moving averages until revenue growth closes some of its gap with the sector median. Revenue grew 17.10% year on year in the latest quarter, against a sector median of 24.2%, and that gap is the main thing the market is weighing against a trailing P/E of 47.58, well above the sector median of 35.1. Analysts are more constructive than the tape: the median 12-month target is $257.11, with a range from $190.00 to $320.00, and eight of 35 analysts rate the stock buy or strong buy. For the shares to recover toward that target, the price would first need to reclaim the 20-day EMA at $225.20 and then the 200-day SMA at $227.97. A further fall would test the 52-week low at $169.63, and a return of growth toward the sector pace would be the condition most likely to change the picture. A simulation based on past volatility is not a forecast, but a typical daily move of 3.58% means the path can be bumpy in either direction.

Support below the price: the 52-week low at $169.63 is the nearest level beneath the shares and the one a further decline would meet first. Resistance above the price: the 20-day EMA at $225.20 is the nearest level overhead, followed by the 200-day SMA at $227.97 and the 50-day SMA at $229.59. These three averages sit close together just above the price, so a move back through them would be a meaningful test of whether sellers are still in control. The 52-week high at $406.94 is far above and would only be relevant after a sustained recovery.